US20100136115A1 - Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation - Google Patents
Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation Download PDFInfo
- Publication number
- US20100136115A1 US20100136115A1 US11/990,040 US99004006A US2010136115A1 US 20100136115 A1 US20100136115 A1 US 20100136115A1 US 99004006 A US99004006 A US 99004006A US 2010136115 A1 US2010136115 A1 US 2010136115A1
- Authority
- US
- United States
- Prior art keywords
- titanium dioxide
- lesion
- pharmaceutical compound
- dispersion
- dioxide composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to a composite comprising titanium dioxide having photocatalytic activity and a pharmaceutical compound having drug efficacy, and particularly relates to a titanium dioxide composite with which a pharmaceutical compound is decomposed by photoexcitation of titanium dioxide to lose drug efficacy thereof.
- titanium dioxide is used for foods and its safety has been confirmed to a certain level. It has been attempted that such titanium dioxide is administered in vivo to utilize its photocatalytic activity.
- WO2004/087765 proposes a titanium dioxide composite in which a molecule having molecular recognition ability binds to titanium dioxide through a hydrophilic polymer. It is attempted that this composite is introduced in a living body, then collected in a specific tissue or cells in the body by the molecule having molecular recognition ability, and irradiated with light to destroy the tissue or cells by the redox power of titanium dioxide.
- this WO publication does not disclose or suggest destruction of a molecule having molecular recognition ability itself supported in the composite by the redox power of titanium dioxide.
- DDS drug delivery system
- Japanese Patent Application Laid-Open Publication No. 7-69900 Japanese Patent Application Laid-Open Publication No. 5-955, Japanese Patent Application Laid-Open Publication No. 2-300133, and the like describe techniques combined with a polymer.
- improvement is still required in terms of efficient delivery to cancer cells, further suppression of adverse drug reactions and the like.
- Japanese Patent Application Laid-Open Publication No. 2002-316946 and Japanese Patent Application Laid-Open Publication No. 2002-316950 disclose a technique in which a drug, especially adriamycin, is supported on metal particles coated with titanium dioxide having photocatalytic activity and then introduced into cancer cells by a gene gun. It is said that when a drug is desired to be detoxified, the drug can be decomposed by a photocatalyst by UV irradiation in this technique. Since this technique premises the use of a gene gun, a special device, and a drug is supported by simple physical adsorption, however, there is room for improvement in terms of versatility and stability.
- the present inventors have now found that a composite in which a pharmaceutical compound binds to titanium dioxide having a photocatalytic activity through a hydrophilic polymer is stable in an aqueous solvent and easy to be administered into a living body and that adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the living body and irradiating the composite with a light to photoexcite titanium dioxide to decompose the pharmaceutical compound in the regions where the drug efficacy of the pharmaceutical composition is not required.
- the present invention is based on these findings.
- an object of the present invention is to provide a titanium dioxide composite that can be stably dispersed in an aqueous solvent, easily be administered into the body and allow drug efficacy of a pharmaceutical compound supported therein to disappear by light irradiation. It is also an object of the present invention to provide a dispersion thereof.
- the titanium dioxide composite according to the present invention comprises a titanium dioxide particle, a hydrophilic polymer bonded to the surface of the titanium dioxide particle, and a pharmaceutical compound having a desired drug efficacy and bonded to the hydrophilic polymer, wherein the pharmaceutical compound is decomposed by photoexcitation of the titanium dioxide to allow the drug efficacy to disappear.
- the dispersion according to the present invention comprises the titanium dioxide composite dispersed in an aqueous solvent, and this dispersion is used in a method comprising the steps of administering the dispersion to an animal, and subsequently irradiating with UV light a region other than the lesion at least surrounding the lesion, without irradiating the lesion, to photoexcite titanium dioxide in the titanium dioxide composite contained in the dispersion, so that a pharmaceutical compound is decomposed by photoexcitation of the titanium dioxide to allow the drug efficacy to disappear.
- the method of treating a lesion comprises the steps of administering the dispersion to an animal including human, and subsequently irradiating with UV light a region other than the lesion at least surrounding the lesion, without irradiating the lesion, to photoexcite titanium dioxide in a titanium dioxide composite contained in the dispersion, so that a pharmaceutical compound is decomposed by photoexcitation of the titanium dioxide to allow the drug efficacy to disappear.
- the use according to the present invention is use of the titanium dioxide composite in the manufacture of a agent for treating a lesion, wherein the agent for treating the lesion is used in a method comprising the steps of administering the agent for treating the lesion to an animal including human, and subsequently irradiating with UV light a region other than the lesion at least surrounding the lesion, without irradiating the lesion, to photoexcite titanium dioxide in a titanium dioxide composite contained in the agent for treating the lesion, so that a pharmaceutical compound is decomposed by photoexcitation of the titanium dioxide to allow the drug efficacy to disappear.
- FIG. 1 shows the relationship between the titanium oxide content of a nanoparticle dispersion liquid of polyacrylic acid-coated titanium oxide prepared in Example 1 and absorption of UV light.
- FIG. 2 shows changes in body weight of mice injected with a dispersion liquid of titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 3 into oral tissue depending on the presence/absence of UV light irradiation.
- FIG. 3 shows the test results of an antitumor effect of titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized in Example 6.
- FIG. 4 shows the test results of an antitumor effect of titanium oxide nanoparticles coated with polyacrylic acid on which bleomycin is immobilized in Example 9.
- the titanium dioxide composite according to the present invention basically comprises titanium dioxide, a hydrophilic polymer bonded to the surface of the titanium dioxide, and a pharmaceutical compound having a desired drug efficacy and bonded to the hydrophilic polymer.
- the titanium dioxide constituting the composite according to the present invention is not particularly limited as long as it has a photocatalytic activity, and may be, for example, either an anatase type or a rutile type. Since the anatase type generally has a greater photocatalytic activity than the rutile type, the anatase type is preferably used.
- the particle size of the titanium dioxide particle may be appropriately selected, considering that the particles are difficult to be aggregated and the particles are introduced into the body.
- the particle size is preferably 2 to 200 nm, and further preferably about 50 to about 200 nm when its accumulation in body tissues, especially in cancer cells, is desired.
- the titanium dioxide particle of the present invention may be combined with another material as long as the titanium dioxide is present on at least part of the surface of a particle and exhibits photocatalytic activity.
- the titanium oxide particle may be a composite of a magnetic material and titanium dioxide.
- the hydrophilic polymer used in the present invention is preferably water soluble and has both a functional group capable of bonding to the surface of a titanium dioxide particle and a functional group capable of bonding to a pharmaceutical compound having a drug efficacy described below.
- this hydrophilic polymer preferably has both a function to stably disperse the titanium dioxide particle in water and a characteristic to provide an appropriate pH as described below.
- the hydrophilic polymer is not limited in terms of structure, molecular weight, or the like, as long as it satisfies the above requirements. According to the preferred embodiment of the present invention, however, the hydrophilic polymer preferably has a plurality of carboxyl groups. Preferred examples thereof include carboxymethyl starch, carboxymethyl dextran, carboxymethyl cellulose, polycarboxylic acids and copolymers having carboxyl groups. More specifically, polycarboxylic acids such as polyacrylic acid and polymaleic acid, and copolymers of acrylic acid/maleic acid and acrylic acid/sulfonic acid monomers, and the like are more suitably used from the viewpoint of hydrolyzability and solubility of the water-soluble polymer. According to a preferred embodiment of the present invention, the molecular weight of the hydrophilic polymer is preferably about 2,000 to about 100,000, and more preferably its lower limit is about 5,000 and its upper limit is about 30,000.
- the hydrophilic polymer can be bonded to the surface of the titanium dioxide particle by a reaction between the functional group of the hydrophilic polymer and a hydroxyl group generated on the surface of the titanium oxide particle by hydration of titanium oxide with water in the reaction system.
- the hydrophilic polymer has a carboxyl group
- the titanium dioxide particles and the hydrophilic polymer may be dispersed in dimethylformamide and a hydrothermal reaction may be performed at 90 to 180° C. for 1 to 12 hours to bond them through an ester bond.
- the ester bond can be confirmed by various analytical methods, and for example, according to the presence of infrared absorption at around 1700 to 1800 cm ⁇ 1 that is an absorption band of an ester bond by the infrared absorption spectrophotometry.
- the pharmaceutical compound used in the present invention is a compound having a predetermined drug efficacy and used for the treatment or prevention of an established disease.
- the present invention is advantageously applied to a pharmaceutical compound that causes severe adverse drug reactions and is thus desired to be delivered only to cells or tissue to be treated as much as possible.
- anticancer drugs for example, antimetabolites (such as 5-fluorouracil, doxifluridine, UTF, methotrexate), antitumor antibiotics (such as doxorubicin, mitomycin C, bleomycin, adriamycin), gold derivatives (cisplatin, nedaplatin), alkylating agents (such as cyclophosphamide), topoisomerase inhibitors (such as irinotecan, etoposide), and plant alkaloids (such as taxol).
- antimetabolites such as 5-fluorouracil, doxifluridine, UTF, methotrexate
- antitumor antibiotics such as doxorubicin, mitomycin C, bleomycin, adriamycin
- gold derivatives cisplatin, nedaplatin
- alkylating agents such as cyclophosphamide
- topoisomerase inhibitors such as irinotecan
- this hydrophobicity advantageously makes uptake of the titanium dioxide composite into cells efficient.
- the hydrophobicity has an advantage that the titanium dioxide composite according to the present invention can be efficiently accumulated in cancer cells.
- a pharmaceutical compound is bonded by a reaction of a functional group of the hydrophilic polymer bonded to the surface of the titanium dioxide particle with a functional group of the pharmaceutical compound.
- Functional groups involved in the bonding between them may be appropriately selected.
- a hydrophilic polymer has a carboxyl group
- a pharmaceutical compound preferably has an amino group, aldehyde group, or the like. Even if a pharmaceutical compound has no such appropriate functional group, an appropriate functional group can be introduced to bond the pharmaceutical compound to a hydrophilic polymer, as far as the introduction does not affect drug efficacy.
- Such a pharmaceutical compound bonded to a hydrophilic polymer through a functional group is particularly preferable, since the compound is stably supported by the titanium dioxide particle and does not detach or diffuse before it reaches a lesion when it is administered into the body of an animal as described below.
- the titanium dioxide composite according to the present invention is constituted such that a pharmaceutical compound is decomposed by a redox reaction caused by photoexcitation of titanium dioxide to allow the drug efficacy thereof to disappear.
- a pharmaceutical compound bonds to a water-soluble polymer through a functional group thereof, one functional group is lost theoretically.
- a functional group of a water-soluble polymer involved in bonding is a carboxyl group
- loss of the carboxyl group due to bonding to a pharmaceutical compound may affect its water solubility and thus may affect dispersibility of the titanium dioxide composite.
- a titanium oxide-polyacrylic acid composite having a particle size of 2 to 200 nm in which a pharmaceutical compound is adriamycin and a water soluble polymer is polyacrylic acid has about 1 to about 1,000 mmol of free carboxylic groups per gram of titanium oxide.
- bonding of a pharmaceutical compound involves activation and substitution of this functional group, loss of about 1% of the carboxylic group does not appear to substantially affect dispersibility. Therefore, according to this embodiment, adriamycin can be bonded to about 1/100 to about 1/1,000 of the carboxyl groups.
- the amount of adriamycin bound can be about 0.001 to about 100 mg and is preferably about 0.1 to 10 mg, more preferably about 0.5 to about 5 mg per gram of titanium dioxide.
- the titanium dioxide composite according to the present invention is stably dispersible in an aqueous solvent due to hydrophilicity of the hydrophilic polymer.
- a hydrophilic polymer has a carboxyl group
- a repulsive force derived from a negative charge of the carboxyl group acts between the composites in an aqueous solvent and the composites are thus stably dispersed.
- the titanium dioxide composite according to the present invention can be stably present in an aqueous solvent in a wide pH range, and for example, a homogenously dispersed state without aggregation can be maintained at pH 3 to 13.
- the titanium dioxide composite according to the present invention can be made into a form of homogenous and stable dispersion liquid in water, buffers at various pHs, infusion liquid, physiological saline solution, etc. Since this dispersion liquid is not likely to aggregate even under near-neutral physiological conditions, a stable oral or parenteral dosage form can be provided. Particularly, this dispersion liquid can be administered to an animal through an injection preparation that is injected directly to a lesion or by intravenous injection, without requiring a special device or the like. An ointment or a spray preparation containing this dispersion liquid can also be applied directly onto a lesion such as the skin.
- the dosage form thereof may be appropriately determined taking into consideration a type of a pharmaceutical compound and a disease and a lesion to be treated, and the dispersion according to the present invention is advantageously applicable to a variety of dosage forms. Further, according to the present invention, an administration route that allows concentration and accumulation of the titanium dioxide composite in a lesion is preferable.
- titanium dioxide composite after administration of the titanium dioxide composite into the body, preferably, titanium dioxide composite is concentrated and accumulated in a lesion and then UV light is irradiated not on the lesion but on a region other than the lesion at least surrounding the lesion. Titanium dioxide is photoexcited by the light irradiation and exhibits redox power. The redox power decomposes a pharmaceutical compound supported on the composite. As a result, drug efficacy of the pharmaceutical compound disappears, and at the same time, adverse drug reactions are also eliminated. According to the present invention, drug efficacy of a pharmaceutical compound can be thus exhibited only at a lesion requiring treatment and influence of the pharmaceutical compound can be eliminated in the other regions where the pharmaceutical compound is not required.
- light for photoexcitation of titanium dioxide is not particularly limited as long as the light can cause photoexcitation of titanium dioxide
- its wavelength is preferably 400 nm or less and UV light having a wavelength of 280 nm is more preferable in relation to a band gap of titanium dioxide.
- Specific light source and apparatus for irradiation may be appropriately determined, selected, and designed.
- sunlight, an ordinary UV lamp, a black light, and the like can be preferably used.
- a UV fiber is mounted to an endoscope for light irradiation.
- treatment can be conducted using an anticancer drug, especially adriamycin, as a pharmaceutical compound, and targeting a cancer tissue as a lesion.
- an anticancer drug especially adriamycin
- the dispersion liquid was placed in a 100 mL vial bottle and subjected to ultrasonic treatment at 200 Hz for 30 minutes.
- the average particle sizes of the dispersion liquid before and after ultrasonic treatment were 36.4 nm and 20.2 nm, respectively.
- the solution was concentrated to prepare an anatase-type titanium dioxide sol having a solid content of 20%.
- An aliquot of 0.75 mL of the anatase-type titanium dioxide sol thus obtained was dispersed in 20 mL of dimethylformamide (DMF), and 10 mL of DMF containing 0.3 g of polyacrylic acid (average molecular weight: 5,000, Wako Pure Chemical Industries, Ltd.) dissolved therein was added and mixed by stirring.
- the solution was transferred into a hydrothermal reaction vessel (HU-50, SAN-AI Science Co., Ltd.), and synthesis was performed at 150° C. for 5 hours. After the completion of the reaction, the vessel was cooled until the temperature of the vessel was 50° C. or lower.
- adriamycin hydrochloride a solution of adriamycin hydrochloride (SERVA) dissolved in DMSO at 2 mg/mL was added and reaction was conducted while stirring at 4° C. for 30 minutes.
- the reaction product was thoroughly dialyzed against PBS to obtain a dispersion liquid of titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized.
- the titanium oxide content obtained by the ash analysis as described in Example 1 was 3.67% (w/v).
- the concentration of adriamycin was measured using free adriamycin as a reference and a fluorospectrophotometer (HITACHI F4010) at an excitation wavelength of 505 nm and a fluorescence wavelength of 575 nm.
- the adriamycin concentration of this dispersion liquid was 23.9 mg/mL. Accordingly, the adriamycin/titanium oxide ratio of this dispersion liquid was found to be 0.653 mg/g of titanium oxide.
- ICR mice Male, body weight: 30 to 35 g
- mice Five to ten ICR mice (male, body weight: 30 to 35 g) were given one-shot intravenous injection of the polyacrylic acid-coated titanium oxide nanoparticle dispersion liquid that is described in Example 1 and had been buffer exchanged into PBS from the tail vein.
- Titanium oxide Total titanium Number of mice given Number of Dose concentration oxide dose administration dead mice Safety (mL) (mg/mL) (%) (mg) (mice) (mice) (%) Sample 0.5 10 1 5 10 5 50 0.5 1 0.1 0.5 10 10 100 0.5 0.1 0.01 0.05 10 10 100 4 0.1 0.01 0.4 3 3 100 PBS 0.5 0 0 0 7 7 100 5 0 0 0 4 4 100
- T24 cells derived from human bladder cancer in the logarithmic growth phase were cultured in an F-12 medium supplemented with 10% fetal bovine serum and inoculated to a 6 cm dish at about 100 cells/dish.
- the titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 2 were added to the cells and the cells were cultured in a CO 2 incubator for 24 hours. After 24 hours, the cells were washed with PBS to remove the titanium oxide component and the F-12 medium supplemented with 10% fetal bovine serum was added. After the cells were cultured for 10 days, viable cells were counted by Giemza staining to determine colony-forming activity.
- a PBS buffer was used as a control.
- the nanoparticles were found to exhibit cytotoxicity on cancer cells even at a concentration as low as about 10 ⁇ g titanium oxide/mL.
- the dispersion liquid of titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 2 was injected into the oral tissue of mice, and inflammation of the tongue was observed and body weight was measured to confirm adverse drug reactions to the particles.
- the tongue of Wistar rats male, 11-week-old, body weight 240 to 260 g was fixed with forceps and 0.3 mL of the 0.005% (w/v) dispersion liquid of titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized was injected into the tongue.
- Black light at the strength of 2500 ⁇ W/cm 2 was immediately irradiated to the tongue for 30 minutes after the injection in one group (14 rats). No UV light treatment was given to another group.
- T24 cells derived from human bladder cancer were cultured using an F12 medium at 37° C. under 5.5% CO 2 gas atmosphere.
- the T24 cells were inoculated to a nude mice (BALV/c, male) to form a tumor.
- the diameter of the tumor was about 5 to 7 mm
- 200 ⁇ L of the 0.05% (w/v) titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 2 was injected.
- a PBS solution was used and the same operation was conducted.
- UV light (2500 ⁇ W/cm 2 ) was irradiated for 1 minute.
- the tumor volume of the nude mice was measured over 3 weeks. The results are shown in FIG. 3 .
- a superior antitumor effect was obtained by the titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized as compared to the control. In addition, the effect was suppressed by UV irradiation.
- the results conform to the above-described results that adriamycin was decomposed by the photocatalytic effect, and the titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized are quite effective in actual therapy.
- the reaction product was thoroughly dialyzed against PBS to obtain a dispersion liquid of titanium oxide nanoparticles coated with polyacrylic acid on which bleomycin is immobilized.
- the titanium oxide concentration obtained by measurement of absorbance at 205 nm was 1.14% (w/v).
- the bleomycin potency of this dispersion liquid assayed by the paper method was 10.5 ⁇ g potency/mL. Accordingly, the bleomycin/titanium oxide ratio of this dispersion liquid was found to be 0.921 mg potency/g of titanium oxide.
- Example 4 The study was conducted as in Example 4, except that the titanium oxide nanoparticles coated with polyacrylic acid on which bleomycin is immobilized prepared in Example 8 were used in place of the titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 2. The results are shown in the following table.
- Example 4 The study was conducted as in Example 4, except that the titanium oxide nanoparticles coated with polyacrylic acid on which bleomycin is immobilized prepared in Example 8 were used in place of the titanium oxide nanoparticles coated with polyacrylic acid on which adriamycin is immobilized prepared in Example 2. The results are shown in FIG. 4 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005228015 | 2005-08-05 | ||
JP2005-228015 | 2005-08-05 | ||
JP2006171781A JP5044150B2 (ja) | 2005-08-05 | 2006-06-21 | 光照射により薬効を消失させる医薬二酸化チタン複合材 |
JP2006-171781 | 2006-06-21 | ||
PCT/JP2006/315499 WO2007018147A1 (fr) | 2005-08-05 | 2006-08-04 | Matériau composite de dioxyde de titane pharmaceutique dont on peut supprimer l’effet pharmacologique par irradiation de lumière |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/315499 A-371-Of-International WO2007018147A1 (fr) | 2005-08-05 | 2006-08-04 | Matériau composite de dioxyde de titane pharmaceutique dont on peut supprimer l’effet pharmacologique par irradiation de lumière |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/889,753 Division US8431143B2 (en) | 2005-08-05 | 2010-09-24 | Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100136115A1 true US20100136115A1 (en) | 2010-06-03 |
Family
ID=37727330
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/990,040 Abandoned US20100136115A1 (en) | 2005-08-05 | 2006-08-04 | Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation |
US12/889,753 Expired - Fee Related US8431143B2 (en) | 2005-08-05 | 2010-09-24 | Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/889,753 Expired - Fee Related US8431143B2 (en) | 2005-08-05 | 2010-09-24 | Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation |
Country Status (3)
Country | Link |
---|---|
US (2) | US20100136115A1 (fr) |
JP (1) | JP5044150B2 (fr) |
WO (1) | WO2007018147A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2458705C1 (ru) * | 2011-06-17 | 2012-08-20 | Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) | Способ получения наноразмерной системы доставки антибиотиков ряда блеомицина в клетки млекопитающих |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017247B2 (en) | 2007-03-30 | 2011-09-13 | Alcoa Inc. | Self cleaning aluminum alloy substrates |
US7910220B2 (en) | 2007-07-25 | 2011-03-22 | Alcoa Inc. | Surfaces and coatings for the removal of carbon dioxide |
US8617665B2 (en) | 2009-08-03 | 2013-12-31 | Alcoa, Inc. | Self-cleaning substrates and methods for making the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783178A (en) * | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
US20060264520A1 (en) * | 2003-03-31 | 2006-11-23 | Shuji Sonezaki | Surface-modified titanium dioxide fine particles and dispersion comprising the same, and method for producing the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2517760B2 (ja) | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
US5330760A (en) * | 1992-08-27 | 1994-07-19 | Sterling Winthrop Inc. | Effervescent antacid |
JP3682475B2 (ja) | 1993-08-31 | 2005-08-10 | 靖久 桜井 | 水溶性抗癌剤 |
US6462017B1 (en) * | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
JP2002316946A (ja) | 2001-04-19 | 2002-10-31 | Japan Science & Technology Corp | 光触媒の生体内への注入方法ならびに生体内への打ち込み粒子およびその製造方法 |
JP2002316950A (ja) | 2001-04-19 | 2002-10-31 | Japan Science & Technology Corp | 薬剤等の注入方法および患部打ち込み粒子の製造方法 |
WO2003033143A1 (fr) * | 2001-10-10 | 2003-04-24 | Noritake Co.,Limited | Matiere photocatalytique inactivant de maniere selective une substance biologiquement nocive et utilisation associee |
JP2003116534A (ja) | 2001-10-18 | 2003-04-22 | Noritake Co Ltd | 有害物質の処理材、有害物質の処理装置およびその処理システム |
US6780437B2 (en) * | 2001-10-23 | 2004-08-24 | Upsher-Smith Laboratories, Inc. | Coated potassium chloride granules and tablets |
EP1614694A4 (fr) | 2003-03-31 | 2008-11-05 | Toto Ltd | Complexe de dioxyde de titane ayant une molecule reconnaissable |
-
2006
- 2006-06-21 JP JP2006171781A patent/JP5044150B2/ja not_active Expired - Fee Related
- 2006-08-04 US US11/990,040 patent/US20100136115A1/en not_active Abandoned
- 2006-08-04 WO PCT/JP2006/315499 patent/WO2007018147A1/fr active Application Filing
-
2010
- 2010-09-24 US US12/889,753 patent/US8431143B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783178A (en) * | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
US20060264520A1 (en) * | 2003-03-31 | 2006-11-23 | Shuji Sonezaki | Surface-modified titanium dioxide fine particles and dispersion comprising the same, and method for producing the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2458705C1 (ru) * | 2011-06-17 | 2012-08-20 | Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) | Способ получения наноразмерной системы доставки антибиотиков ряда блеомицина в клетки млекопитающих |
Also Published As
Publication number | Publication date |
---|---|
US20110014245A1 (en) | 2011-01-20 |
US8431143B2 (en) | 2013-04-30 |
JP2007063253A (ja) | 2007-03-15 |
WO2007018147A1 (fr) | 2007-02-15 |
JP5044150B2 (ja) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thakur et al. | Synthesis and biomedical applications of nanoceria, a redox active nanoparticle | |
Shirin et al. | Advanced drug delivery applications of layered double hydroxide | |
Yang et al. | Titanium-based sonosensitizers for sonodynamic cancer therapy | |
He et al. | Combined photothermal and antibiotic therapy for bacterial infection via acidity-sensitive nanocarriers with enhanced antimicrobial performance | |
EP1834646B1 (fr) | Accelerateur de therapie cancereuse ultrasonique et agent cytotoxique | |
KR102081666B1 (ko) | 암 치료용 약학 조성물 | |
US20040068207A1 (en) | Active oxygen generator containing photosensitizer for ultrasonic therapy | |
WO2011102407A1 (fr) | Agent de radiothérapie | |
EP2649623A1 (fr) | Formulations de nanoparticules magnétiques, procédés de fabrication de ces formulations, et procédés pour leur utilisation | |
Ma et al. | Rationally integrating peptide-induced targeting and multimodal therapies in a dual-shell theranostic platform for orthotopic metastatic spinal tumors | |
Zhang et al. | NIR light-induced tumor phototherapy using photo-stable ICG delivery system based on inorganic hybrid | |
CN113751079B (zh) | 一种生物材料负载的钙钛矿-二氧化钛纳米复合光催化剂及其构建方法和应用 | |
US8431143B2 (en) | Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation | |
Geng et al. | Oxygen-carrying biomimetic nanoplatform for sonodynamic killing of bacteria and treatment of infection diseases | |
Li et al. | Folate receptor-targeting mesoporous silica-coated gold nanorod nanoparticles for the synergistic photothermal therapy and chemotherapy of rheumatoid arthritis | |
Zhang et al. | Persistent luminescence-activated Janus nanomotors with integration of photodynamic and photothermal cancer therapies | |
CN110302395B (zh) | 一种可促肿瘤凝血和酶/pH双重响应性释药的纳米粒子及其制备方法与应用 | |
Unnikrishnan et al. | Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review | |
Alavijeh et al. | Cancer therapy by nano MIL-n series of metal-organic frameworks | |
CN112546025B (zh) | 一种Ce6@CMCS-DSP-IPI549抗肿瘤纳米传递系统的制备方法 | |
CN109846857A (zh) | 一种活性天然超分子光敏剂的制备方法及其应用 | |
CN110251672B (zh) | 一种纳米诊疗剂及其制备方法与应用 | |
Wan et al. | Titania-coated gold nanorods as an effective carrier for gambogic acid | |
CN114848843B (zh) | 一种化疗协同靶向联合治疗纳米药物及其在肿瘤治疗中的应用 | |
Yang et al. | Preparation and in vitro evaluation of doxorubicin loaded alendronate modified hollow gold nanoparticles for bone-targeted chemo-photothermal therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TOTO LTD.,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SONEZAKI, SHUJI;KANEHIRA, KOKI;OGAMI, YUMI;AND OTHERS;SIGNING DATES FROM 20070110 TO 20070117;REEL/FRAME:021826/0731 |
|
AS | Assignment |
Owner name: TOTO LTD.,JAPAN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATES "2007" TO-2008--FOR EACH INVENTOR AND SPELLING OF CITY ASSIGNEE "KITAKYUSYU-SHI" TO-KITAKYUSHU-SHU-, PREVIOUSLY RECORDED ON REEL 021826 FRAME 0731. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:SONEZAKI, SHUJI;KANEHIRA, KOKI;OGAMI, YUMI;AND OTHERS;SIGNING DATES FROM 20080110 TO 20080117;REEL/FRAME:021904/0409 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |